Clinical outcomes and response predictors of Vedolizumab induction treatment for Korean patients with inflammatory Bowel diseases who failed Anti-TNF therapy: A KASID Prospective multicenter Cohort study

IBD Research Group of the Korean Association for the Study of Intestinal Diseases

Research output: Contribution to journalArticlepeer-review

2 Scopus citations

Abstract

Background: We investigated the real-life effectiveness and safety of vedolizumab (VDZ) induction therapy among Korean patients with Crohn disease (CD) or ulcerative colitis (UC) for whom anti-tumor necrosis factor therapy previously failed. Methods: Adult patients who started VDZ induction therapy at 16 centers were prospectively enrolled in the Korean VDZ nationwide registry. The coprimary outcomes were clinical remission, defined as a Crohn's Disease Activity Index score <150 points and a partial Mayo score ≤2 points with a combined rectal bleeding and stool frequency subscore ≤1 point at week 14 and endoscopic remission defined as a Mayo endoscopic subscore ≤1 point. We also analyzed predictors of clinical remission. Results: Between August 2017 and November 2019, a total of 158 patients (80 with CD and 78 with UC) received VDZ induction therapy. Clinical remission rates among patients with CD and patients with UC were 44.1% and 44.0%, respectively. Among patients with UC, the endoscopic remission rate was 32.4%. Clinical response and remission rates showed increasing trends during induction therapy. Multivariable analysis revealed that clinical response at week 6 was the only predictor of clinical remission at week 14 for both patients with CD and patients with UC. Among patients who experienced 1 or more adverse events (n = 71; 44.9%), disease exacerbation (n = 28; 17.7%) was the most common adverse event. Conclusions: Among Korean patients with CD or UC for whom anti-tumor necrosis factor therapy failed, VDZ induction therapy was effective and safe. The early clinical response was associated with clinical remission after VDZ induction therapy.

Original languageEnglish
Pages (from-to)1931-1941
Number of pages11
JournalInflammatory Bowel Diseases
Volume27
Issue number12
DOIs
StatePublished - 1 Dec 2021

Keywords

  • Crohn disease
  • Korea
  • Ulcerative colitis
  • Vedolizumab

Fingerprint

Dive into the research topics of 'Clinical outcomes and response predictors of Vedolizumab induction treatment for Korean patients with inflammatory Bowel diseases who failed Anti-TNF therapy: A KASID Prospective multicenter Cohort study'. Together they form a unique fingerprint.

Cite this